<DOC>
	<DOCNO>NCT00295724</DOCNO>
	<brief_summary>- The primary objective placebo-controlled clinical trial evaluate analgesic efficacy safety bicifadine 200 mg BID compare placebo patient moderate severe chronic low back pain . - The secondary objective evaluate effect bicifadine function general quality life , evaluate safety follow discontinuation bicifadine treatment investigate population pharmacokinetics bicifadine .</brief_summary>
	<brief_title>Efficacy Safety Bicifadine Treatment Chronic Low Back Pain</brief_title>
	<detailed_description />
	<mesh_term>Back Pain</mesh_term>
	<mesh_term>Low Back Pain</mesh_term>
	<criteria>Main Patients low back pain assess Class 1 , Class 2 Class 3 accord Quebec Task Force Classification Spinal Disorders without detectable leg weakness neurological examination . Patients pain categorized Class 1 accord Quebec Task Force Classification must RolandMorris Disability Rating &gt; 17 baseline qualify . Patients pain categorized Class 2 Class 3 accord Quebec Task Force Classification must RolandMorris Disability Rating least 10 baseline qualify . Patients must require daily analgesic treatment low back pain least 3 month prior dose . Main Patients may persistent moderate severe pain location low back ( exception radiation low extremity ) . Patients must lower back surgery within 6 month prior baseline , epidural corticosteroid injection within 3 month prior baseline . Patients may unstable medical condition .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2007</verification_date>
	<keyword>bicifadine</keyword>
	<keyword>chronic low back pain</keyword>
</DOC>